Health Care · Pharmaceutical Preparations · Tokyo Stock Exchange · CIK 1395064 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $17.25Day −2.82%1Y +26.8%Off 52W high −8.7%Vol (1Y) 21.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 4,164 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Days to cover1.3d |
| Top-10 13F concentration62.3% |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)JPY 4.58T |
| Earnings (TTM)JPY 107.93B |
| ROE1.5% |
| Net margin2.4% |
| ROIC1.9% |
| Debt / equity0.65× |
| Total debt / EBITDA4.09× |
| EPS growth 3Y−22.8% |
| Sales growth 3Y8.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (JPY). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+10.6% |
| 1Y+26.8% |
| 3Y+20.7% |
| 5Y+11.7% |
| 10Y−20.9% |
| Since incept. (ann.)−0.9% |
Total return through 2026-07-30 · series begins 2010-01-05. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)21.5% |
| Ann. volatility (3Y)19.7% |
| Sharpe (1Y)0.99 |
| Sharpe (3Y)0.42 |
| Max drawdown (1Y)−20.1% |
| Max drawdown (3Y)−21.2% |
| Beta (3Y vs SPY)−0.26 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Capital Research Global Investors | 19.1M | $354M | — | +41.7% |
| FMR LLC | 7.1M | $132M | — | +75.4% |
| MORGAN STANLEY | 6.5M | $120M | — | +1.5% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.4M | $119M | — | new |
| GOLDMAN SACHS GROUP INC | 5.6M | $104M | — | +16.9% |
| BRANDES INVESTMENT PARTNERS, LP | 4.4M | $82M | — | +14.1% |
| BlackRock, Inc. | 3.2M | $59M | — | +16.3% |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3.1M | $58M | — | −45.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
No reported quarters on file for TAK.
